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Abstract
MyD88 signaling directly promotes T cell survival, and is required for optimal T cell responses to 
pathogens. To examine the role of T cell intrinsic MyD88 signals in transplantation, we studied 
mice with targeted T cell-specific MyD88 deletion. Contrary to expectations, we found that these 
mice were relatively resistant to prolongation of graft survival with anti-CD154 plus rapamycin in 
a class II mismatched system. To specifically examine the role of MyD88 in Tregs, we created a 
Treg specific MyD88-deficient mouse. Transplant studies in these animals replicated the findings 
observed with a global T cell MyD88-knockout. Surprisingly, given the role of MyD88 in 
conventional T cell survival, we found no defect in the survival of MyD88-deficient Tregs in vitro 
or in the transplant recipients, and also observed intact cell homing and expression of Treg effector 
molecules. MyD88-deficient Tregs also fail to protect allogeneic bone marrow transplant 
recipients from chronic graft versus host disease, confirming the observations of defective 
regulation seen in a solid organ transplant system. Together, our data define MyD88 as having a 
divergent requirement for cell survival in non-Tregs and Tregs, and a yet-to-be defined survival-
independent requirement for Treg function during the response to alloantigen.
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Introduction
The Myeloid Differentiation Primary Response Gene 88 (MyD88) is a key adaptor molecule 
downstream of all Toll-like receptors (TLRs) except TLR-3, as well as the IL-1 receptor 
(IL-1R) and family members (IL18R and IL-33R) (1, 2). Although traditionally thought of 
as a key molecule for innate immune responses, MyD88 has a critical, T cell intrinsic role. 
Previously, we have demonstrated that in T cells, MyD88 activates both the NF-ΚB and 
phosphoinositide 3-kinase (PI3K) pathways, ultimately promoting proliferation, IL-2 
production and survival in vitro (3, 4). In vivo, T cell expressed MyD88 is required for 
resistance to the protozoan parasite T. gondii (5) and for optimal T cell survival in vivo, 
during the early stages of acute lymphocytic choriomeningitis virus (LCMV) infection (6, 
7). In the latter case the requirement for MyD88 is linked to its role in IL-33 signaling (8).
The role of MyD88 signals during transplantation has been studied as well. Germline 
MyD88 deficiency in both donor and recipient leads to long-term skin engraftment without 
immunosuppression in a minor antigen (H-Y) mismatch model (9), and facilitates induction 
of long-term survival by costimulatory blockade in MHC mismatched skin transplantation 
(10). Conversely, we and others have shown that treatment of mice with TLR ligands can 
abrogate the skin or cardiac allograft prolonging effects of costimulatory blockade (CoB) 
(11-13). In most of the above models, CD4+Foxp3+ regulatory T cells (Tregs) are critical for 
the promotion of long-term allograft survival and tolerance (14). Similar to naïve and 
effector T cells, Tregs express many TLRs and stimulation of these TLRs on mouse and 
human Tregs can both enhance or inhibit the suppressive function of Tregs in vitro and in 
vivo (15-17). For example, treatment of Tregs with flagellin during an in vitro suppression 
assay resulted in decreased proliferation of effector T cells, suggesting that TLR-5 
engagement resulted in increased Treg suppressive function (18). In contrast, TLR-2 
engagement with Pam3CSK4 did not decrease Treg function in vitro and in vivo, but rather 
promoted Treg survival via induction of Bcl-xL (19). While these data demonstrate a role for 
MyD88 signals in the alloimmune response, the use of germline MyD88 knockout mice 
precluded determining its cell specific roles.
To investigate this issue focusing on the role of MyD88 in T cells, we utilized conditional 
knockout mice whereby MyD88 was deleted specifically in all T cells or confined to Tregs. 
We found that mice that lacking MyD88 in their T cells or Tregs were relatively resistant to 
the induction of long-term survival of MHC class II mismatched skin and cardiac grafts. 
MyD88-deficient Tregs also failed to protect allogeneic bone marrow transplant recipients 
from chronic graft versus host disease. Contrary to expectations, we found no survival defect 
in MyD88-deficient Tregs. These data uncover an important survival-independent role for 
MyD88 during the alloimmune response.
Materials and Methods
Mice
Mice with a T cell specific deletion of MyD88, termed MyD88-ΔT mice, have been 
previously described (6). Mice with a Foxp3+ Treg specific deletion of MyD88, termed 
MyD88-ΔTreg animals, were produced by crossing Foxp3-Cre mice (20) to MyD88fl/fl mice 
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(Fig. S1). Foxp3-Cre, MyD88fl/fl, MyD88-ΔT and MyD88-ΔTreg mice were maintained as 
breeding colonies in our animal facility. C57Bl/6, B6(C)-H2-Ab1bm12/KhEgJ (bm12), 
B10.BR and Foxp3tm1Kuch (FoxP3-GFP) mice (21) were obtained from The Jackson 
Laboratory (Bar Harbor, ME). All colonies were maintained in accordance with the 
protocols approved by the Institutional Animal Care and Use Committees of the 
Massachusetts General Hospital and the University of Minnesota.
Skin transplantation and treatment
Skin transplantation was performed as described (22). Animals were monitored daily for 
rejection (defined as >80% necrosis). Where indicated, mice received 0.25mg anti-CD154 
(clone: MR1, BioXcell, Lebanon, NH) and 1mg/kg rapamycin (LC Laboratories, Woburn, 
MA) in a carboxy methyl cellulose and Tween 80 solution as described (11).
Cardiac transplantation and treatment
Heterotopic heart transplantation was performed as previously described (23). Graft survival 
was assessed by daily palpation. Where indicated, mice received 0.5×106 Treg (defined as 
CD4+GFP+ cells, isolated by cell sorting from FoxP3-GFP mice) via retro-orbital injection 7 
days prior to heart transplantation.
Induction of chronic GVHD
cGVHD was induced as previously described in B10.BR recipients exposed to 8.3Gy X-ray 
irradiation prior to infusion of C57BL/6 bone marrow and 0.07×106 splenic T cells from 
FoxP3-Cre or MyD88-ΔTreg mice (24). Tests to measure pulmonary function were 
performed as previously decribed (24). Briefly, mice were anesthetized, weighed, and lung 
function was assessed by whole body plethysmography using the Flexivent FX system 
(Scireq). Data was analyzed using the Flexivent software version 7.6.
Antibodies and flow cytometry
Single cell suspensions were prepared in PBS supplemented with 2% BSA and 0.1% sodium 
azide and stained with the mAbs to the following molecules purchased from BioLegend 
(San Diego, CA); CD4 (GK1.5), CD8 (53-6.7), CD25 (PC61), CD44 (IM7), CD62L 
(MEL-14), CD45 (30-F11) Thy1.2 (53-2.1), TCRβ (H57-597), Annexin V, IFN-γ 
(XMG1.2), IL-17A (TC11-18H10.1), CD28 (37.51), CTLA-4 (UC10-4B9), PD-1 (29F.
1A12), GITR (DTA-1), granzyme B (NGZB), CD39 (Duha59), CD73 (TY/11.8) and Lag 3 
(C9B7W). mAb to Foxp3 (FJK-16s) was purchased from eBioscience (San Diego, CA). 
Live/Dead Aqua was purchased from Life Technologies (Grand Island, NY). 7-AAD was 
purchased from BD Biosciences (Franklin Lakes, NJ). Cell fixation and permeabilization 
was performed using the Intracellular Fix/Perm Buffer Set (eBiosceince). For studies 
utilizing YFP expressing cells, , cell fixation with 2% paraformaldehyde prior to above fix/
perm procedure was performed to preserve YFP fluorescence. Flow cytometric analysis was 
performed on LSRII (BD Biosciences, San Jose, CA) or Navios (Beckman Coulter, Brea, 
CA) flow cytometers. Data analysis was performed using Flow Jo (version 10.0.7 Tree Star, 
Ashland, OR).
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Histology
After harvesting, skin grafts were embedded in Tissue-Tek OCT Compound (Sakura Finetek 
USA, Torrance, CA), and submerged in liquid nitrogen for 20 seconds. 10μm sections were 
fixed to slides in acetone for 5 minutes at −20 degrees Celsius and stained for 1 hour with 
αCD4 PE (GK1.5) (BioLegend) and DAPI (Life Technologies) at room temperature. Image 
analysis and merging was performed using ImageJ (Version 1.48).
Skin digestion
Skin grafts were harvested as described (25), and digested into a single cell suspension for 
60-90 minutes. Where indicated, single cell suspensions were incubated with Leukocyte 
Activation Cocktail (BD Biosciences) for 2 hours at 37°C before staining for flow 
cytometry.
In vitro culture
Purified (StemCell Technologies, Vancouver, BC) CD4+ T cells from pooled spleens and 
peripheral lymph nodes were sorted for naïve cells (CD4+CD62Lhi CD44−CD25−Foxp3−), 
or Tregs (CD4+Foxp3+ or CD4+CD25+ cells on a SORP FACS ARIA II (BD Biosciences, 
San Jose, CA). 2-5×105 cells were then resuspended in complete RPMI media and plated in 
a 48-well plate with 5μg/mL plate bound anti-CD3 and anti-CD28 (BioLegend), a 96-well 
flat bottom plate with 5μg/mL plate bound anti-CD3 and 1μg/mL anti-CD28, or a 96-well 
round bottom plate with 3×105 APCs treated with mitomycin C (Sigma-Aldrich, St. Louis, 
MO) and 2μg/mL anti-CD3. Plates were incubated at 37°C for 72 hours. When indicated, 
cells were incubated with Leukocyte Activation Cocktail for 4 hours after indicated culture 
time. In vitro suppression assays were performed as described in (26).
Western Blotting
CD4+YFP− and CD4+YFP+ cells were sorted using FACS to greater than 95% purity. 
Western blotting was performed as described in (26). αMyD88 (1:200 dilution) was 
purchased from R&D Systems (Minneapolis, MN) and α–β-actin (1:1000 dilution) was 
purchased from Cell Signaling (Danvers, MA).
Results
T cell expressed MyD88 is critical for bm12 allograft survival
As a first step to determine the role of T cell expressed MyD88 during the alloimmune 
response, we transplanted bm12 skin onto wild-type (WT) or MyD88fl/fl × CD4-Cre 
(MyD88-ΔT) mice. Significantly delayed rejection in this model can be induced by anti-
CD154 plus rapamycin (hereafter termed costimulatory blockade CoB) (11). We observed 
that untreated MyD88-ΔT mice rejected bm12 skin allografts with similar kinetics (MST= 
11 days) as untreated WT mice (MST=14 days; Fig. 1A). As expected, CoB prolonged graft 
survival (>50 days) in the majority of wild-type recipients, however we noted a non-
statistically significant trend towards more rapid rejection in the MyD88-ΔT recipient 
animals. In this same strain combination, bm12 → B6, significantly delayed rejection of 
cardiac allografts is reliably achieved without immunosuppression (27-29), and consistent 
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with prior studies untreated WT mice accepted bm12 cardiac allografts with a MST greater 
than 100 days (MST undefined). In contrast, we found that MyD88-ΔT mice rejected their 
grafts with a MST of 39 days (Fig. 1B, p=0.0012). These data indicate that T cell intrinsic 
MyD88 is not only dispensable for rejection, but may be required for prolongation of graft 
survival.
We and others have shown that successful long-term engraftment of bm12 skin and heart 
transplants in B6 mice is Treg dependent (11, 29), and thus we hypothesized that a defective 
regulatory response in MyD88-ΔT mice could account for the findings above. To test this, 
we asked whether adoptive transfer of WT Tregs into MyD88-ΔT mice prior to bm12 
cardiac transplant would rescue bm12 cardiac allograft survival. Indeed, infusion of 0.5×106 
sorted WT Foxp3+ cells 7 days prior to transplantation was sufficient to reconstitute 
“normal” graft survival (MST undefined; Figure 1B, p=0.0213). Taken together, these 
experiments demonstrate that T cell expressed MyD88 is critical for Treg-dependent 
prolongation of graft survival.
Treg expressed MyD88 is dispensable for Treg survival
Previously, we have shown a survival defect of MyD88-deficient T cells during the in vivo 
immune response to a pathogen (6, 7). We hypothesized given the large precursor frequency 
of alloreactive cells (30), that a survival defect might not have an impact on rejection 
kinetics but could affect the less numerous alloresponsive Treg population. To directly 
analyze whether MyD88 was critical for Treg survival, we cultured naïve T cells or Tregs 
(defined as CD4+CD25+) from WT or MyD88-ΔT mice with anti-CD3, anti-CD28 with or 
without IL-2. Consistent with our previously published findings in vivo findings (6, 7), we 
found reduced survival (defined as AnnexinV+7-AAD+) among stimulated MyD88-deficient 
naïve T cells compared to WT cells (Figure 2A and B). Surprisingly however, we found that 
no significant difference in survival in the two the Treg populations (Figure 2A and B).
To more directly address the role of MyD88 in Tregs, we crossed MyD88fl/fl mice with 
Foxp3YFP-Cre mice to generate animals with a Treg-specific MyD88 deficiency (MyD88-
ΔTreg). We first bred female MyD88fl/fl mice to be heterozygous for Foxp3YFP-Cre. Since 
the Foxp3 locus is on the X chromosome, due to random X-chromosome inactivation, these 
mice should have a 50:50 ratio of Cre+YFP+ MyD88-deficient T regs to Cre−YFP− MyD88-
sufficient Tregs thus allowing us to assess the survival of MyD88-deficient Tregs in vivo 
under competitive conditions. Using serial bi-weekly bleeds from age 6-36 weeks, we found 
no significant difference in the percentage of YFP+ cells between control Foxp3YFP-Cre/+ 
mice, Foxp3YFP-Cre/+ mice with a single floxed-MyD88 allele, and Foxp3YFP-Cre/+ mice 
with both alleles of MyD88 floxed (Fig. 2C). Moreover, in each of these groups of mice, the 
percentage of YFP+ cells did not alter over time 7 months of observation. Due to the 
variation in YFP+ cell frequency from mouse to mouse, the percentage of YFP+ cells among 
the total Foxp3+ population was not significantly different between the three groups of mice. 
However we do observe a trend towards lower percentages of YFP+ cells within the 
MyD88fl/+ Foxp3YFP-Cre/+ het and MyD88fl/fl Foxp3YFP-Cre/+ het groups. The fact that there 
is not a gene-dosage effect, i.e., levels of YFP+ cells in the single allele knockout mice 
(MyD88fl/+ Foxp3YFP-Cre/+ het) are lower than in either the wild-type mice (Foxp3-Cre het) 
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or the double allele knockout mice (MyD88fl/fl Foxp3YFP-Cre/+ het) argues against an actual 
MyD88-related effect. Thus, these data demonstrate equivalent in vivo survival of MyD88-
deficient and wild-type Tregs under homeostatic conditions.
To further characterize MyD88-deficient Tregs, we next asked whether loss of MyD88 
resulted in a difference in Treg expression of several hallmark Treg proteins, i.e., CTLA-4, 
Lag-3, Granzyme B, CD39 and CD73, all of which have been implicated in Treg function 
(26, 31-39). We observed no difference in the expression of any of the above markers on 
MyD88-deficient Tregs relative to WT Tregs that were analyzed directly ex vivo, or 
activated in vitro with anti-CD3 plus anti-CD28 for 20 or 72 hours (Figure 3A-E). In 
addition, MyD88-deficient Tregs functioned equivalent to WT Tregs in a standard in vitro 
suppression assay (Figure 3F).
Treg expressed MyD88 is critical for prolonged bm12 skin graft survival
We next examined graft survival in MyD88-ΔTreg mice. Similar to the observations in mice 
with MyD88-deleted in all T cells, we observed that MyD88-ΔTreg mice treated with CoB 
rejected bm12 skin grafts at a higher frequency than WT recipients (MST: 37 days and 
undefined respectively; Figure 4, p=0.0008). To corroborate these observations with our 
finding above (Fig. 1) that adoptive transfer of WT Tregs could prevent rejection of bm12 
cardiac allografts in MyD88-ΔT recipients, we utilized FoxP3 YFP-Cre/+ mice to assess 
whether a complement of WT Tregs could promote allograft survival in MyD88-ΔTreg 
mice. Indeed, we found that rejection of bm12 skin allografts was delayed in CoB treated 
MyD88fl/fl FoxP3 YFP-Cre/+ recipients (MST: 59 days) compared with MyD88-ΔTreg 
recipients (MST: 37 days; Figure 3). Together, these data demonstrate that Treg expressed 
MyD88 is critical for delay of bm12 skin graft rejection using CoB.
MyD88 deficient Tregs efficiently migrate to and survive within bm12 skin grafts
Tregs within the allograft (intragraft Tregs) are critical for graft survival, suggesting that 
observation of similar Treg frequencies in the periphery may not be indicative of the 
inability for MyD88-deficient Tregs to promote long-term allograft survival locally (40, 41). 
Having observed no defect in MyD88-ΔTregs either in vitro, or in the steady state, in vivo, it 
was therefore important to examine their migrational ability and survival in transplanted 
animals. To assess the ability of MyD88-deficient Tregs to migrate to the skin graft, we first 
analyzed the expression of CCR4, CCR6 and CD103, three receptors important for skin 
homing (42-44). There were no differences in the expression of CCR4, CCR6 or CD103 
across time points within the spleen or pLN from MyD88-ΔTreg or WT recipients pre-
transplant, or 7, 14 and 21 days post transplant (data not shown), suggesting that MyD88-
deficient Tregs would be able to migrate to the skin efficiently.
We did not observe any difference in Foxp3+ T cell frequency in blood, spleen or peripheral 
lymph nodes from MyD88-ΔTreg or WT recipients pre-transplant or 7, 14 and 21 days post 
transplant (data not shown), and as well the frequencies of Tregs isolated from bm12 skin 
grafts 7 and 14 days post transplant were similar. However, at day 21 post transplant, we 
observed a significant decrease in Tregs harvested from MyD88-ΔTreg recipients in 
comparison to WT recipients (Fig. 5A). However based on a bead-based cell counting assay, 
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we found that grafts harvested from MyD88-ΔTreg and WT recipients contained the same 
number of Tregs while the non-Treg number significantly increased in MyD88-ΔTreg 
recipients, indicating that the decreased Treg frequency was the result of an increase in non-
Treg absolute number (Fig. 5B and 5C). Of note, there was no difference in the viability of 
intragraft Tregs harvested from WT vs. MyD88-ΔTreg recipients (Fig. 5D), nor in their 
localization with the graft as both types of cells homed to the hypodermal region (Fig. 5E). 
Together, the above data demonstrate that MyD88-deficient Tregs migrate and persist in 
bm12 skin grafts at similar numbers and in the same location within the graft as do WT 
Tregs.
Next, we asked whether a Treg survival defect was revealed following activation in vitro in 
the presence of CoB. To accomplish this, we activated sorted MyD88-deficient Tregs from 
MyD88-ΔTreg mice with anti-CD3 and anti-CD28 in the presence of 1ng/mL, 10ng/mL and 
100ng/mL of rapamycin with or without 100μg/mL anti-CD154. As seen in Figure 5F, these 
drug concentrations did not result in a lower frequency of Annexin V- 7-AAD- cells, 
indicating that Treg survival did not decrease despite blocked proliferation in the presence of 
these drugs (data not shown). Importantly, at each concentration, no significant difference in 
the frequency of Annexin V− 7-AAD− between WT or MyD88-deficient Tregs was observed 
(Fig. 5F), further confirming our findings that MyD88 was dispensable for Treg survival.
Impaired suppression by MyD88-deficient Tregs in GVHD
We considered that the impaired in vivo suppression we observed might be a situation 
specific to the skin transplant model. To test a distinct in vivo model of alloantigen 
responsiveness we utilized a model of chronic GVHD (cGVHD) induced by infusion of 
bone marrow cells and splenic T cells. In this model, where disease pathology is manifest as 
immunoglobulin deposition in the lung and liver, the splenic T cells are critical for 
supporting B cells to become antibody secreting cells that are required for cGVHD 
generation and maintenance (45). Similar to the results seen with skin transplantation, 
MyD88-deficient Tregs were unable to mediate optimal protection of B6 recipients of 
B10.BR bone marrow from cGVHD. We observed that recipients of MyD88-deficient 
splenocytes, despite having similar elastance to recipients of WT splenocytes, had 
significantly higher airway resistance and lower compliance, indicating that MyD88-
deficient Tregs were not able to protect from cGVHD as efficiently as WT Tregs (Figure 6A-
D). Importantly recipients of either WT or MyD88-deficient splenocytes had comparable 
survival and body weights, indicating that these mice did not experience acute GVHD.
Discussion
Our data demonstrate the unexpected finding of a regulatory T cell-intrinsic role for MyD88 
in the ability to modulate the response to alloantigens in vivo. Using models of skin and 
heart transplantation, as well as chronic GVHD, all of which have defined roles for Tregs in 
restraining the allo-effector response, MyD88-deficient T cells had diminished in vivo 
function. While an obvious mechanistic candidate for this finding is impaired cell survival, 
given the known defect in survival of naïve MyD88-deficient T cells responding to 
pathogens, we found no abnormalities in cell viability in vivo or in vitro between MyD88-
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deficient and wild-type Tregs. Therefore, the more rapid rejection of bm12 allografts by 
MyD88-ΔTreg recipients, as well as the inability of MyD88-ΔTreg splenocytes to protect 
from cGVHD indicates a cell-survival independent defect.
In naïve T cells, the p85 subunit of PI3K associates with tyrosine 257 in the TIR domain of 
MyD88, which then phosphorylates AKT and GS3K, synergizing with CD28 signaling 
leading to a proliferative response and IL-2 production. Additionally, in the absence of 
CD28 signaling, MyD88-dependent TLR-9 signaling leads to NF-κB and Bcl-xL expression 
and enhanced the survival of T cells.(3, 4) Interestingly, in a standard model of adoptive 
transfer-induced colitis, MyD88-deficient effector T cells could not induce a wasting 
phenotype and colonic inflammation in Rag−/− recipients. This suggests that MyD88 may 
also promote T cell function in addition to cell survival. Similarly, MyD88-deficient Tregs 
were unable to protect Rag−/− recipients of effector T cells as well as WT Tregs from colitis 
like disease, suggesting that MyD88-deficient Tregs do not function equivalently to WT 
Tregs. (46) Furthermore, Treg intrinsic MyD88 signaling has been shown to negatively 
regulate Foxp3 by promoting expression of IRF1, which binds to IRF1 response elements in 
the Foxp3 promoter (47). Together, the above data demonstrates that Treg and T cell 
expressed MyD88 can modulate cell survival and function. Thus it may appear paradoxical 
that in our transplant models using mice in which MyD88 is lacking in the entire T cell 
compartment, the dominant effect observed is due to loss of MyD88 in Tregs. We believe the 
likely explanation for this observation is the extremely large and vigorous nature of the 
alloreactive response, in which large numbers of cells are recruited very early and expand 
rapidly with the result that a defect in survival of effector T cells would be “sub-clinical”.
During transplantation, MyD88 may be activated following ligation of TLRs and/or the 
IL-1R family of receptors. Recently, haptoglobin, a molecule released from necrotic cells, 
was described to be upregulated in skin grafts following transplantation. Furthermore, 
expression of haptoglobin accelerated graft rejection while genetic deletion of haptoglobin 
in the donor delayed rejection kinetics in a MyD88 dependent, but TLR-2 and 4 independent 
manner (48). In addition, Pam3Cys, PolyI:C, LPS and CpG DNA, all microbial products, 
abrogated the allograft prolonging effects of CoB further indicating that innate immune 
activation via the TLR signaling pathways promotes rejection and results in the inability to 
induce long-term allograft survival (11-13).
The IL-1R family member IL-33R, one of the upstream receptors of MyD88, prolongs 
cardiac allograft survival, despite promoting TH2 associated cytokines (49, 50). Prolongation 
of graft survival in IL-33 treated recipients is dependent on Tregs and recipient expression of 
IL-33R, and is associated with an increase in intragraft Tregs.(51) More recently, IL-33 was 
shown to stimulate IL-2 production by dendritic cells which selectively expanded 
suppressive IL-33R+ Tregs, demonstrating a potential mechanism for its action.(52) 
Together, these data demonstrate that MyD88 signals can either promote or inhibit allograft 
survival, the net result likely being context dependent.
Previous work has shown that MyD88-expression in Tregs is important to promote mucosal 
tolerance (53). In those studies, loss of Treg MyD88 resulted in a relative deficiency of 
intestinal Tregs, and exacerbated IL-17-dependent inflammation in experimental colitis. 
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Additionally, T follicular regulatory cells were decreased both in number and in function, 
leading to a dysbalance in IgA and alterations in intestinal flora. The potential mechanism(s) 
by which loss of MyD88 might perturb Treg function remains under investigation, but may 
include alterations in cell metabolism given the recently described critical role of TLR 
signaling in driving metabolic reprogramming in dendritic cells to enable optimal activation 
and function (54).
Our data highlight the importance of cell-type specific targeting of inflammatory pathways 
during the alloimmune response. Targeting of inflammatory pathways has been 
demonstrated to improve allograft survival, as inhibition of TNF-α has been shown to 
prolong cardiac allograft survival in rats and intestinal transplantation in patients (55, 56). 
As targeted therapeutics become more advanced, it may be possible to target MyD88, or 
other inflammatory pathways, specifically in dendritic cells and/or non-Tregs, resulting in 
enhanced long-term allograft survival and tolerance.
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Figure 1. 
A. bm12 skin allografts were transplanted onto WT or MyD88-ΔT recipients. Mice received 
either no treatment (● and ∎, respectively), or i.p. injection of 0.25 mg αnti-CD154 (Clone: 
MR1, administered on Days 0, 2 and 4) and i.p. injection of 1 mg/kg rapamycin 
(administered on Days 0, 2, 4, 6, 8, 10 and 12) (❍ and ◻, respectively). Data are pooled 
from 2 independent experiments. MST: 13, 11, 90, 53 days (●, ∎, ❍, ◻) respectively. B. 
bm12 cardiac allografts were transplanted into WT or MyD88-ΔT recipients. Mice received 
either no treatment (●and ∎, respectively), or i.v. injection of 0.5×106 sorted WT Tregs 
(isolated from FoxP3GFP mice 7 days prior to transplant (◻). Data are pooled from 2 
independent experiments. MST: undefined, 34 days, and undefined (●,∎,◻) respectively. *, 
p<0.05. **, p<0.01.
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Figure 2. 
A. Representative flow cytometry plots of sort-purified CD4+CD25+ Tregs or 
CD4+CD25+CD62L+CD44− naïve, non- Tregs from WT (white bars) or MyD88-ΔT (black 
bars) mice stained with annexin V and 7-AAD after 72 hours of in vitro culture with anti-
CD3 and anti-CD28, with and without 10 ng/mL IL-2. Numbers in lower-left quadrant 
indicate frequency of cells within that quadrant. B. Quantification of data from 5 
independent experiments of A. C. Female MyD88+/+ Foxp3+/Cre-YFP (Foxp3-Cre-YFP het) 
MyD88fl/+ FoxP3+/Cre-YFP (MyD88fl/+ Foxp3-Cre-YFP het) and MyD88fl/flxFoxp3+/Cre-YFP 
(MyD88fl/fl Foxp3-Cre-YFP het) mice were bled bi-weekly starting at 6 weeks of age for 26 
weeks. Percent YFP positive cells were assessed among total Foxp3+CD4+ antibody stained 
cells. Data are pooled from a minimum of 2 independent experiments. Error bars display 
standard deviation. **, p<0.01.
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Figure 3. 
WT (black lines and black bars, minimum n=10 mice) and MyD88-ΔTreg (red lines and red 
bars, minimum n=11 mice) CD4+Foxp3+ cells were isolated from pooled spleen and 
peripheral lymph nodes. Cells were analyzed directly ex vivo, or stimulated with anti-CD3 
and anti-CD28 for 20 hours. At each time point, A. CD39 and CD73, B. surface CTLA-4, C. 
intracellular CTLA-4, D. Lag-3 and E. Granzyme B were assessed. Shaded gray area 
indicates appropriate isotype control for indicated stain. Representative flow cytometry plots 
shown from a minimum of 3 independent experiments. F. In vitro suppression assay. 
Quantification of percent proliferation of WT naïve T cells co-cultured with irradiated APCs 
and indicated ratios of WT (black bars) or MyD88-ΔTreg (red bars) (normalized to 
proliferation of WT naïve cells without Treg). Data are pooled from 5 independent 
experiments. Error bars display standard deviation.
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Figure 4. 
bm12 skin allografts were transplanted onto WT (n=14 recipients, 7 male Cre-hemizygous 
mice, 7 female homozygous mice). MyD88fl/flFoxp3+/Cre heterozygous (n=5 female Cre 
heterozygous recipients) or MyD88-ΔTreg (n=12 recipients, 8 male Cre-hemizygous mice, 4 
female Cre-homozygous mice) treated with CoB as in Figure 1.1 (❍, ◇ and ◻, 
respectively). Data are pooled from 3 independent experiments. MST: undefined, 37 and 59 
days (❍, ◇, ◻) respectively. ***, p<0.001.
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Figure 5. 
A. bm12 skin grafts were harvested from WT (white bars, n≥5) or MyD88-ΔTreg (black 
bars, n≥3) recipient mice, and frequency of Foxp3+ CD4+ cells was assessed by flow 
cytometry at each indicated time point post transplant. B & C. Intragraft Foxp3+ (panel B) 
and Foxp3− (panel C) cellularity was calculated using the number of CD45+ cells isolated 
from WT (white bars, n=5) or MyD88-ΔTreg (black bars, n=6) recipient mice with a bead 
based flow cytometric counting assay; data are representative of 2 independent experiments. 
D. Skin grafts were harvested from WT (white bars, n=5) or MyD88-ΔTreg (black bars, 
n=6) recipient mice, digested and stained for Foxp3 and with Live/Dead Aqua. Frequency of 
Live/Dead Aqua positive cells are indicated, data are representative of 2 independent 
experiments. E. Fluorescent imaging of skin grafts from WT or MyD88-ΔTreg recipient 
mice. Sections were imaged at 10x and 40x magnification. White box on 10x magnification 
images indicate area imaged with 40x objective. Data are representative of grafts harvested 
from n=6 WT mice and n=8 MyD88-ΔTreg mice. F. Frequency of Annexin V- 7-AAD- WT 
(white bars) or MyD88-ΔTreg (black bars) Treg after activation and culture with anti-CD3, 
anti-CD28 and IL-2 with indicated concentrations of αnti-CD154 and/or rapamycin for 72 
hours. Quantification of data from a minimum of 3 independent experiments. Error bars 
display standard deviation. *, p<0.05.
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Figure 6. 
A. Mouse weight and B. survival curve following induction of cGVHD in B10.BR mice 
following B6 bone marrow transplant (●) and B6 bone marrow transplant plus adoptive 
transfer of either WT (❍) or MyD88-ΔTreg (◻) splenocytes. C. Airway resistance and D. 
compliance measured on Day 28 post BMT from recipients of B10.BR bone marrow alone 
(gray bars), B10.BR bone marrow plus WT splenocytes (white bars) or B10.BR bone 
marrow plus MyD88-ΔTreg splenocytes (black bars). Error bars display standard error of the 
mean. *, p<0.05. **, p<0.01. ***, p<0.001.
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